Full Archive
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary staging. Calculate the proportion of…
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos exposure, mostly affects the pleura. The pleura is the membrane that surrounds the lungs. It can also harm tissues like the peritoneum, which is a membrane that surrounds the abdomen. Due to its rare nature and shared symptoms with other illnesses, diagnosing mesothelioma is very tough.…
A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the body including the lungs, abdomen, heart, and testicles. This has led experts to believe that in future cases of mesothelioma, dietary changes could improve treatment…
Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for targeted therapies. The test works by finding complex DNA patterns that are common in mesothelioma cells. The new approach is more accurate than standard mesothelioma…
A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically for Keytruda alongside pemetrexed and platinum chemotherapy. The approval follows the promising results in phases 2 and 3 of the Keynote-483 trial. The trial consisted…
Mesothelioma is a rare, aggressive cancer mainly caused by asbestos exposure. One treatment that is giving hope to patients and caregivers is the use of immune checkpoint inhibitors. A new study from Australia has raised questions about the effectiveness and safety of this novel treatment. In order to best care for patients, caregivers need to…
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
Mesothelioma is a difficult diagnosis to receive. With this diagnosis comes treatment regimens and their effects on the body. The United Kingdom has a new set of standard treatments for mesothelioma which include Ipilimumab and Nivolumab. A new article in the journal Lung Cancer reviews Ipilimumab and Nivolumab results, using a study from a UK…
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not be the best option due to the person’s age and other health problems. Chimeric antigen receptor (CAR) T cell therapy shows promise when treating different…
A pleural mesothelioma diagnosis is incredibly overwhelming for patients and caregivers. Knowing about treatment options can make it easier on these groups. One area of research is looking at blood-based biomarkers to test for mesothelioma. Two promising biomarkers are soluble mesothelin-related protein and cancer antigen 125. Both help monitor pleural mesothelioma progression. A new article…
